Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?

The prognosis for patients with locally advanced or metastatic breast cancer (mBC) remains poor, with a median survival of 2–4 years. About 10% of newly diagnosed breast cancer patients present with metastatic disease, and 30%–50% of those diagnosed at earlier stages will subsequently progress to mB...

Descripción completa

Detalles Bibliográficos
Autores principales: Cazzaniga, Marina Elena, Biganzoli, Laura, Cortesi, Laura, De Placido, Sabino, Donadio, Michela, Fabi, Alessandra, Ferro, Antonella, Generali, Daniele, Lorusso, Vito, Milani, Andrea, Montagna, Emilia, Munzone, Elisabetta, Orlando, Laura, Pizzuti, Laura, Simoncini, Edda, Zamagni, Claudio, Pappagallo, Giovanni L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Expert Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485034/
https://www.ncbi.nlm.nih.gov/pubmed/31114242
http://dx.doi.org/10.2147/OTT.S189163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485034/
https://www.ncbi.nlm.nih.gov/pubmed/31114242
http://dx.doi.org/10.2147/OTT.S189163

Ejemplares similares